ArticleGut1992
Oncogenes and onco-suppressor gene in adenocarcinoma of the oesophagus.
Article in Gut, 1992. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 138 citations in OpenAlex.
- MiR-193a-5p/ERBB2 act as concurrent chemoradiation therapy response indicator of esophageal squamous cell carcinoma.Oncotarget · 2016Article
- Esophageal carcinoma cell line with high EGFR polysomy is responsive to gefitinib.Langenbeck's archives of surgery · 2014Article
- Human epidermal growth factor receptor-2 in oesophageal cancers: an observational study.World journal of gastroenterology · 2012Article
- Clinicopathological characteristics of human epidermal growth factor receptor 2-positive Barrett's adenocarcinoma.World journal of gastroenterology · 2012Article
- Involvement of CXCR4 chemokine receptor in metastastic HER2-positive esophageal cancer.PloS one · 2012Article
- Current status of SRC inhibitors in solid tumor malignancies.The oncologist · 2011Review
- Low Level of Her-2 Locus Amplification by Fluorescent In Situ Hybridization Does Not Correlate with Her-2 Protein Overexpression by Immunohistochemistry in Barrett's Esophagus.Journal of oncology · 2010Article
- MUC4 is increased in high grade intraepithelial neoplasia in Barrett's oesophagus and is associated with a proapoptotic Bax to Bcl-2 ratio.Journal of clinical pathology · 2004Article
- Barrett's oesophagus and adenocarcinoma.World journal of surgical oncology · 2004Article
- Cell cycle regulation in patients with intestinal metaplasia at the gastro-oesophageal junction.Molecular pathology : MP · 2003Article
- Barrett's esophagus: model of neoplastic progression.World journal of surgery · 2003Review
- Molecular biology of Barrett's adenocarcinoma.Annals of surgery · 2001Review
- Article
- The expression of c-src gene in the carcinogenesis process of human cardia adenocarcinoma.World journal of gastroenterology · 1999Article
- Role of p53 assessment in management of Barrett's esophagus.Digestive diseases and sciences · 1999Review
- Molecular evolution of the metaplasia-dysplasia-adenocarcinoma sequence in the esophagus.The American journal of pathology · 1999Review
- p53 alterations in oesophageal cancer: association with clinicopathological features, risk factors, and survival.Molecular pathology : MP · 1998Article
- Barrett's esophagus. The significance of p53 in clinical practice.Annals of surgery · 1997Review
- The significance of c-erb B-2 and p53 immunoreactivity in patients with adenocarcinoma of the esophagus.Annals of surgery · 1995Article
- c-erbB-2 overexpression in the dysplasia/carcinoma sequence of Barrett's oesophagus.Journal of clinical pathology · 1995Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
While the activation of the proto-oncogenes has been implicated in the development and progression of cancer of many tissues, the role of oncogenes in the development of oesophageal adenocarcinoma has not been defined. Fifteen patients who had undergone resection for oesophageal adenocarcinoma and 15 who had undergone oesophagectomy or biopsy for Barrett's oesophagus were studied. The latter patients also had adjacent normal gastric mucosa biopsied for comparison with the metaplastic oesophageal mucosa. The mucosal samples were snap frozen and subsequently stained with monoclonal antibodies to the following oncogene associated proteins; c-erbB2 (neu and CE-1) (external domain), c-erbB2 (NCL-CB11) (internal domain), c-src, c-ras, c-myc, c-fos, c-jun, and the onco-suppressor gene--p53. All tumours were well or moderately differentiated adenocarcinomas arising from the lower third of the oesophagus. Eleven specimens showed strong membraneous staining with both c-erbB2 (neu) and c-erbB2 (CBL-CB11). Seven specimens showed strong nuclear staining with p53 onco-suppressor gene. Three specimens were positive for c-ras and c-src, and two were positive for c-jun. In Barrett's epithelium, nine specimens were positive for c-erbB2 (neu and CB11), three were positive for c-src, two were positive for c-ras and c-jun, and one was positive for c-fos. Two of the gastric mucosal biopsy specimens expressed c-erbB2 weakly but no other oncogenes were found. The frequency of positive staining for c-erbB2 is very high, compared with the expression of these genes in other tumours. It is also concluded that errors in the onco-suppressor gene p53, and especially in the external and internal domains of c-erbB2, which is also often expressed in Barrett's mucosa, may be implicated in the development of adenocarcinoma of the oesophagus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.